Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-28T05:21:48.617Z Has data issue: false hasContentIssue false
  • English
  • Français

Vaccination for respiratory immunity: latest developments

Published online by Cambridge University Press:  15 December 2009

Richard Harland
Richard Harland*
Affiliation:
Novartis Animal Health Canada, Inc., 208 Pump Hill Gardens SW, Calgary, Alberta T2V 4M6, Canada
*
E-mail: richard.harland@novartis.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Advances over the last 20 years in immunology and molecular biology have provided many new tools for identifying the important antigens and new ways to achieve the appropriate immune responses to these antigens. These provide many more options to achieve the best immune response from deletion mutations, subunit antigens, vectors or DNA immunization. These tools are being adopted to screen, discover and produce the appropriate antigens and to deliver them by the optimal method and with novel adjuvants to achieve the appropriate immune response. These developments will result in vaccines for respiratory disease that are safer and more efficacious, and provide greater flexibility for use and administration.

Keywords

conserved antigensprotective antigensreverse vaccinologyDNA vaccinesDIVA vaccines
Type
Review Article
Information
Animal Health Research Reviews , Volume 10 , Issue 2 , December 2009 , pp. 155 - 158
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Benga, L, Hoeltig, D, Rothkoetter, TJF, Pabst, R and Valentin-Weigand, P (2009). Expression levels of immune markers in Actinobacillus pleuropneumoniae infected pigs and their relation to breed and clinical symptoms. BMC Veterinary Research 5: 13.CrossRefGoogle ScholarPubMed
Chang, Y, Young, R, Post, D and Struck, D (1987). Identification and characterization of the Pasteurella haemolytica leukotoxin. Infection and Immunity 55: 2348–2354.CrossRefGoogle ScholarPubMed
Dudek, T and Knipe, DM (2005). Replication-defective viruses as vaccines and vaccine vectors. Virology 344: 230–239.CrossRefGoogle Scholar
Hammond, JM and Johnson, MA (2005). Porcine adenovirus as a delivery system for vaccines and immunotherapeutics. The Veterinary Journal 169: 17–27.CrossRefGoogle ScholarPubMed
Harandi, AM, Davies, G and Olesen, OF (2009). Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Reviews Vaccines 8: 293–298.CrossRefGoogle ScholarPubMed
Hernandez, A, Karrow, N, Wilkie, BN and Mallard, BA (2002). High and low immune responsiveness of dairy cattle: microarray analysis of gene expression associated with high and low immune response phenotypes. In: 7th World Congress on Genetics Applied to Livestock Production, 19–23 August 2002, Montpellier, France.Google Scholar
Hornef, M, Wick, M, Rhen, M and Normark, S (2002). Bacterial strategies for overcoming host innate and adaptive immune responses. Nature Immunology 3: 1033–1040.CrossRefGoogle ScholarPubMed
O'Hagan, DT and De Gregorio, E (2009). The path to a successful vaccine adjuvant – ‘the long and winding road’. Drug Discovery Today 14: 541–551.CrossRefGoogle Scholar
Osterhaus, A (2008). New respiratory viruses of humans. The Pediatric Infectious Disease Journal 27: S71–S74.CrossRefGoogle ScholarPubMed
Pasick, J (2004). Application of DIVA vaccines and their companion diagnostic tests to foreign animal disease eradication. Animal Health Research Reviews 5: 257–262.CrossRefGoogle ScholarPubMed
Pizza, M, Scarlato, V, Masignani, V, Giuliani, MM, Aricò, B, Comanducci, M, Jennings, GT, Baldi, L, Bartolini, E, Capecchi, B, Galeotti, CL, Luzzi, E, Manetti, R, Marchetti, E, Mora, M, Nuti, S, Ratti, G, Santini, L, Savino, S, Scarselli, M, Storni, E, Zuo, P, Broeker, M, Hundt, E, Knapp, B, Blair, E, Mason, T, Tettelin, H, Hood, DW, Jeffries, AC, Saunders, NJ, Granoff, DM, Venter, JC, Moxon, ER, Grandi, G and Rappuoli, R (2000). Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287: 1816–1820.CrossRefGoogle ScholarPubMed
Prado, M, Dabo, S and Confer, A (2005). Immunogenicity of iron-regulated outer membrane proteins of Pasteurella multocida A:3 in cattle: molecular characterization of the immunodominant heme acquisition system receptor (HasR) protein. Veterinary Microbiology 105: 269–280.CrossRefGoogle ScholarPubMed
Rappuoli, R (2000). Reverse vaccinology. Current Opinion in Microbiology 3: 445–450.CrossRefGoogle ScholarPubMed
Salonius, K, Simard, N, Harland, R and Ulmer, JB (2007). The road to licensure of a DNA vaccine. Current Opinion in Investigational Drugs 8: 635–641.Google ScholarPubMed
Schwarz, AJF, York, CJ, Zirbell, LW and Estella, LA (1957). Modification of infectious bovine rhinotracheitis (IBR l virus in tissue culture and development of a vaccine). Proceedings of the Society of Experimental Biology and Medicine 96: 453–458.CrossRefGoogle Scholar
Van Drunnen Little-Van Den Hurk, S, Tikoo, S, Liang, X and Babiuk, L (1993). Bovine herpesvirus-1 vaccines. Immunology and Cell Biology 71: 405–442.Google Scholar
van Engelenburg, F, Kaashoek, MJ, Rijsewijk, FAM, van den Burg, L, Moerman, A, Gielkens, ALJ and van Oirschot, J (1994). A glycoprotein E deletion mutant of bovine herpesvirus 1 is avirulent in calves. Journal of General Virology 75: 2311–2318.CrossRefGoogle ScholarPubMed